Nivolumab in the treatment of metastatic squamous non-small . . . Progress in the treatment of patients with advanced stage squamous cell non-small cell lung cancer (NSCLC) has been limited An improvement in the understanding of tumor immunosurveillance has resulted in the development of the immune checkpoint inhibitors such as nivolumab
Non-Small Cell Lung Cancer (NSCLC) Treatment | OPDIVO . . . OPDIVO® (nivolumab) alone, or with YERVOY® (ipilimumab) can be used as an immunotherapy treatment option for adults with certain types of NSCLC Please see Indication and Important Safety Information
Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer The 5-year lung cancer-specific survival rate was 74 9% with nivolumab plus chemotherapy vs 65 1% with chemotherapy alone (HR, 0 65) No new safety concerns emerged, and there were no new deaths
Long-Term Survival Outcomes With First-Line Nivolumab Plus . . . Nivolumab plus ipilimumab–based treatment regimens have shown long-term, durable efficacy benefits in patients with metastatic NSCLC Here we report clinical outcomes from a pooled analysis of patients with metastatic NSCLC and tumor programmed death-ligand 1 (PD-L1) lower than 1% treated with first-line nivolumab plus ipilimumab with or without two cycles of chemotherapy versus up to four